Temozolomide in malignant gliomas: current use and future targets |
| |
| Authors: | J. Lee Villano Tara E. Seery Linda R. Bressler |
| |
| Affiliation: | (1) Section of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, 909 S. Wolcott Ave. Rm. 3133 (M/C 734), Chicago, IL 60612, USA;(2) Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA |
| |
| Abstract: | Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance. |
| |
| Keywords: | Temozolomide Brain tumor Alkylating chemotherapy Malignant glioma Glioblastoma Tumor resistance |
| 本文献已被 SpringerLink 等数据库收录！ |
|
